People · Operator
Named in public records as an officer, director or promoter · active 2015–2026 · Biotechnology, Other, Other Energy, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxess Technologies, Inc. | — | Biotechnology | Series C | $138.2M | $269.9M | 2021 |
| Syzygy Plasmonics Inc. | — | Other | Series C | $110.2M | $824.8M | 2019 |
| Cambridge Crops, Inc. | — | Other | Series C | $85.7M | $617.9M | 2019 |
| Quaise Energy, Inc. | — | Other Energy | Series C | $83.1M | $94.7M | 2020 |
| Kytopen Corp. | — | Biotechnology | Series B | $52.7M | $39.0M | 2019 |
| Lucy Therapeutics, Inc. | — | Pharmaceuticals | Series B | $28.6M | $91.5M | 2019 |
| ImmuneXcite, Inc. | — | Biotechnology | Series A | $17.6M | $96.6M | 2015 |
| Droplet Biosciences, Inc. | — | Biotechnology | Series A | $13.0M | $53.1M | 2021 |
| E25Bio Inc. | — | Biotechnology | Seed | $6.8M | $13.7M | 2019 |
| Kano Therapeutics Inc. | — | Biotechnology | Series A | $5.0M | $28.5M | 2024 |
Ann DeWitt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ann DeWitt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rachel Sha | 3 | 4 |
| Theresa Tribble | 2 | 3 |
| Livio Valenti | 2 | 2 |
| CRAIG SHAPIRO | 1 | 15 |
| Arunas Chesonis | 1 | 11 |
| Peter Kolchinsky | 1 | 8 |
| Mark Cupta | 1 | 8 |
| John Edwards | 1 | 8 |
| Stanley Lapidus | 1 | 7 |
| Aaron Sandoski | 1 | 7 |
| Laura Witt | 1 | 5 |
| Lucas Mann | 1 | 5 |
| Paxton Major | 1 | 5 |
| Eric Rowinsky | 1 | 4 |
| John Ripple | 1 | 4 |
| James Geraghty | 1 | 3 |
| Eric Furfine | 1 | 3 |
| Fenel Eloi | 1 | 3 |
| Michael Biddle | 1 | 3 |
| Michael Schrader | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.